Contact | Print version | PDF version | Send article | RSS feed

OncoMethylome Sciences licenses methylation technologies to Qiagen for commercializing epigenetic applications

14 Nov 2008 - OncoMethylome Sciences announced that it has signed a world-wide, non-exclusive license agreement with QIAGEN. Under this agreement, QIAGEN has licensed certain of OncoMethylome's methylation technologies for use in certain of QIAGEN's future products. These products will expand, among others, QIAGEN's EpiTect product line. The agreement specifically covers the use of OncoMethylome's patented Methylation-Specific PCR (MSP) technology, the most widely applied epigenetic technology, for the scientific research market. Under the terms of the agreement, QIAGEN will pay OncoMethylome an upfront fee plus royalties from future sales of products utilizing this technology. Other terms of the agreement were not disclosed.
 
Herman Spolders, Chief Executive Officer of OncoMethylome Sciences S.A. stated: "We are very pleased to have entered this relationship with QIAGEN, the market leader for sample and assay technologies in molecular diagnostics, applied testing, and pharmaceutical and academic research, which underscores the great value that OncoMethylome's technologies have for the epigenetic cancer research market. The agreement will lead to accelerated research in methylation-based applications for early detection and personalized treatment of cancer."